Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Status Completed

Clinical Trial Summary

A total of 201 participants with chronic HCV GT4 infection were allocated into two groups. One group participants were treated with SOF plus RBV (24 weeks). The second group was treated with SOF plus SMV (12 weeks).

Clinical Trial Description

A total of 201 participants, treatment-naïve and experienced, with chronic HCV GT4 infection were allocated into two groups based on the type of the regimen used. All eligible participants were treated orally with SOF plus daily oral weight-based RBV (24 weeks; group 1), or SOF plus daily oral SMV (12 weeks; group 2). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04385407
Study type	Interventional
Source	Beni-Suef University
Contact
Status	Completed
Phase	Phase 2
Start date	April 2015
Completion date	July 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01708889` - Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction	Phase 1
Active, not recruiting	`NCT00563173` - Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients	Phase 1/Phase 2
Withdrawn	`NCT01813266` - Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Completed	`NCT01121731` - A Phase I/II Clinical Trial With Interferon Alfa 5 in Treatment-Experienced Patients With Genotype-1 Chronic Hepatitis C	Phase 1/Phase 2
Completed	`NCT00851890` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection	Phase 2
Completed	`NCT04387539` - ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants	Phase 1/Phase 2
Completed	`NCT04391985` - Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients	Phase 1/Phase 2
Completed	`NCT00770198` - sgp130 in Chronic Human Liver Disease	N/A
Completed	`NCT04382937` - Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection	Phase 3
Completed	`NCT00606528` - FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy	N/A
Recruiting	`NCT00294489` - Methacetin Breath Test in HCV Patients With Normal and Near-Normal ALT	Phase 3
Withdrawn	`NCT00255359` - Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers	Phase 1
Completed	`NCT00570336` - Study of CTS-1027 in Hepatitis C Patients	Phase 2
Completed	`NCT02292719` - A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection	Phase 2
Terminated	`NCT01080222` - A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection	Phase 2
Completed	`NCT04387526` - Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4	Phase 2/Phase 3
Completed	`NCT00215865` - PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy	Phase 3